Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 20Lymphoid 17Other hematologic neoplasm 8Sarcoma 4CNS 4Plasma cell 3Endocrine 3Genitourinary 2NET 1Gastrointestinal 1Dermatologic 1

Conditions

Neuroendocrine Tumors 1Neuroendocrine Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 10Magnetic Resonance Spectroscopy 10lutetium Lu 177 dotatate 8cabozantinib 4Nivolumab 4Cisplatin 4pembrolizumab 3X-Rays 3Ipilimumab 3Everolimus 3Etoposide 3Carboplatin 3olaparib 2gallium Ga 68 dotatate 2fluorodopa F 18 2fludarabine 2aldesleukin 2Phantoms, Imaging 2Lutetium-177 2Lutetium 2Irinotecan 2Fluorodeoxyglucose F18 2Cyclophosphamide 2CTLA-4 Antigen 2trametinib 1tipifarnib 1sodium thiosulfate 1selpercatinib 1repotrectinib 1peposertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Etoposide × Endocrine × 30 days × Clear all
NCT06132113 2026-05-27

DAREONā„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

NCT06406465 2026-05-27

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
60 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT07544654 2026-05-27

DAREONĀ®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Boehringer Ingelheim

Phase 3 Not yet recruiting
390 enrolled
Endocrine

Extrapulmonary Neuroendocrine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚔